Cite
A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma
MLA
Xiao, Xibin, et al. “A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin’s Lymphoma.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 2094. EBSCOhost, https://doi.org/10.1182/blood-2023-189149.
APA
Xiao, X., Lei, W., Jiang, H., Qiu, X., Li, X., Chen, P., Xu, Y., Xie, H., Song, G., Cheng, Y., Wu, F., Liu, D., Yang, L., & Qian, W. (2023). A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin’s Lymphoma. Blood, 142(1, Number 1 Supplement 1), 2094. https://doi.org/10.1182/blood-2023-189149
Chicago
Xiao, Xibin, Wen Lei, Huawei Jiang, Xi Qiu, Xian Li, Panpan Chen, Yang Xu, et al. 2023. “A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin’s Lymphoma.” Blood 142 (1, Number 1 Supplement 1): 2094. doi:10.1182/blood-2023-189149.